Zacks Research Issues Optimistic Outlook for Qiagen Earnings

Qiagen (NYSE:QGEN - Free Report) - Equities research analysts at Zacks Research raised their Q2 2025 earnings estimates for shares of Qiagen in a report issued on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.59 for the quarter, up from their prior estimate of $0.56. The consensus estimate for Qiagen's current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen's Q4 2025 earnings at $0.62 EPS, FY2025 earnings at $2.32 EPS, Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.60 EPS, FY2026 earnings at $2.43 EPS, Q1 2027 earnings at $0.60 EPS and FY2027 earnings at $2.70 EPS.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The business had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. During the same period last year, the business earned $0.44 EPS. The company's revenue was up 5.2% on a year-over-year basis.

QGEN has been the topic of a number of other reports. UBS Group dropped their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Wall Street Zen upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Finally, Robert W. Baird boosted their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Seven analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $48.42.

Qiagen Stock Up 0.3%

NYSE:QGEN traded up $0.13 during midday trading on Friday, hitting $45.13. 2,518,914 shares of the company were exchanged, compared to its average volume of 1,166,674. The company has a fifty day simple moving average of $41.70 and a 200 day simple moving average of $41.88. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $10.03 billion, a PE ratio of 125.66, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67.

Institutional Trading of Qiagen

Institutional investors have recently added to or reduced their stakes in the stock. SVB Wealth LLC purchased a new stake in shares of Qiagen in the first quarter valued at about $31,000. Brown Brothers Harriman & Co. purchased a new stake in shares of Qiagen in the fourth quarter valued at about $37,000. Geneos Wealth Management Inc. lifted its holdings in shares of Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock valued at $38,000 after purchasing an additional 251 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Qiagen by 152.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock valued at $39,000 after purchasing an additional 526 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Qiagen by 148.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after purchasing an additional 835 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.